No significant news emerged in the year-end report. Promore continues to be focused on the LL-37 study, which progresses according to the plan, and top-line data is expected in Q4 2020. Preparations to advance PXL01 into Phase 3 are ongoing, which is likely to happen during H1 2021, but this requires additional funding. Following the Q4 2019 report, we are not making any model changes and reiterates our base case fair value of SEK 8.4.